Hemophagocytic Lymphohistiocytosis/macrophage Activation Syndrome (HLH/MAS) Following Treatment with Tisagenlecleucel

Overview

Journal Clin Case Rep

Date 2022 Jan 14

PMID 35028140

Authors

Reyes Maria Martin-Rojas

Ignacio Gomez-Centurion

Rebeca Bailen

Mariana Bastos

Francisco Diaz-Crespo

Diego Carbonell

Rafael Correa-Rocha

Marjorie Pion

Cristina Munoz

Milagros Sancho

Isabel Gomez Fernandez

Gillen Oarbeascoa

Ana Perez-Corral

Carolina Martinez-Laperche

Javier Anguita

Ismael Buno

Javier Menarguez

Jose Luis Diez-Martin

Mi Kwon

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T cell-related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with poor prognosis and a challenging diagnosis. The establishment of specific diagnosis criteria is essential, and the combination of several techniques for CAR T-cell follow-up, allows a more precise management of this complication.

Citing Articles

In-depth analysis of the safety of CAR-T cell therapy for solid tumors.

Dong J, Wu J, Jin Y, Zheng Z, Su T, Shao L Front Immunol. 2025; 16:1548979.

PMID: 40066440 PMC: 11891211. DOI: 10.3389/fimmu.2025.1548979.

Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.

Meireles A, Iacoboni G, Moco L, Ramos I, Bras G, Azevedo J Immunotherapy. 2024; 16(18-19):1105-1111.

PMID: 39417342 PMC: 11633410. DOI: 10.1080/1750743X.2024.2409622.

Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention.

Li J, Chen H, Xu C, Hu M, Li J, Chang W Front Immunol. 2024; 15:1422591.

PMID: 39253080 PMC: 11381299. DOI: 10.3389/fimmu.2024.1422591.

The next frontier in immunotherapy: potential and challenges of CAR-macrophages.

Li J, Chen P, Ma W Exp Hematol Oncol. 2024; 13(1):76.

PMID: 39103972 PMC: 11302330. DOI: 10.1186/s40164-024-00549-9.

Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.

Hughes A, Teachey D, Diorio C Semin Immunopathol. 2024; 46(3-4):5.

PMID: 39012374 PMC: 11252192. DOI: 10.1007/s00281-024-01013-w.

References

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Martin-Rojas R, Gomez-Centurion I, Bailen R, Bastos M, Diaz-Crespo F, Carbonell D . Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. Clin Case Rep. 2022; 10(1):e05209. PMC: 8741874. DOI: 10.1002/ccr3.5209. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Vallurupalli M, Berliner N . Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019; 134(21):1783-1786. PMC: 8938935. DOI: 10.1182/blood.2019002289. View

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View

La Rosee P . Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015; 2015:190-6. DOI: 10.1182/asheducation-2015.1.190. View

Schuster S, Bishop M, Tam C, Waller E, Borchmann P, McGuirk J . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 380(1):45-56. DOI: 10.1056/NEJMoa1804980. View

Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D . Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014; 66(9):2613-20. DOI: 10.1002/art.38690. View

Wohlfarth P, Agis H, Gualdoni G, Weber J, Staudinger T, Schellongowski P . Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis. J Intensive Care Med. 2017; 34(9):723-731. DOI: 10.1177/0885066617711386. View

10.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

11.

Locatelli F, Jordan M, Allen C, Cesaro S, Rizzari C, Rao A . Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811-1822. DOI: 10.1056/NEJMoa1911326. View

12.

Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F . Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017; 15(1):47-62. PMC: 6733403. DOI: 10.1038/nrclinonc.2017.148. View

13.

Lehmberg K, Nichols K, Henter J, Girschikofsky M, Greenwood T, Jordan M . Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica. 2015; 100(8):997-1004. PMC: 5004414. DOI: 10.3324/haematol.2015.123562. View

14.

Strati P, Ahmed S, Kebriaei P, Nastoupil L, Claussen C, Watson G . Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020; 4(13):3123-3127. PMC: 7362369. DOI: 10.1182/bloodadvances.2020002328. View

15.

Major A, Collins J, Craney C, Heitman A, Bauer E, Zerante E . Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021; 62(7):1765-1769. PMC: 8282706. DOI: 10.1080/10428194.2021.1881507. View

16.

Schuster S, Maziarz R, Rusch E, Li J, Signorovitch J, Romanov V . Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020; 4(7):1432-1439. PMC: 7160283. DOI: 10.1182/bloodadvances.2019001304. View

17.

Sandler R, Tattersall R, Schoemans H, Greco R, Badoglio M, Labopin M . Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant.... Front Immunol. 2020; 11:524. PMC: 7137396. DOI: 10.3389/fimmu.2020.00524. View

18.

Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S . Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-102. PMC: 2993617. DOI: 10.1182/blood-2010-04-281931. View